March 27th 2024
During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Overview on Advances in GI Malignancy Management with Precision Medicine
October 6th 2023Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, discuss recent updates in the management of gastrointestinal malignancies, with a focus on colorectal cancer and the crucial role of precision medicine in guiding treatment decisions.
Watch
Ivaltinostat Combinations Show Promise for Pancreatic Adenocarcinoma
September 13th 2023In an interview, Mohamad Adham Salkeni, MD, FRCPC, discussed the ongoing study of maintenance ivaltinostat plus capecitabine or capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line FOLFIRINOX.
Read More
IMbrave050: Adjuvant Therapy for High-Risk Hepatocellular Carcinoma
July 26th 2023The Oncology Brothers, joined by Muhammad Shaalan Beg, MD, share their thoughts on data from the IMbrave050 trial investigating adjuvant atezolizumab plus bevacizumab in patients with high-risk hepatocellular carcinoma.
Watch
PROSPECT: Neoadjuvant Therapy for Locally Advanced Rectal Cancer
July 26th 2023Muhammad Shaalan Beg, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from the PROSPECT trial investigating neoadjuvant therapy regimens for the treatment of locally advanced rectal cancer.
Watch
Survival Benefit Shown With IA Gemcitabine in Patients with Locally Advanced Pancreatic Cancer
July 10th 2023In the phase 3 TIGeR-PaC study, intra-arterial administration of gemcitabine demonstrated positive progression-free and overall survival outcomes in patients with locally advanced pancreatic cancer.
Read More
Li Assesses Evolving Therapies in Biliary Tract Cancers
July 7th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, and participants discussed current approaches to treating biliary tract cancers, including the TOPAZ-1 study regimen of cisplatin, gemcitabine, and durvalumab.
Read More
FDA Grants Priority Review to BLA for Zolbetuximab in Advanced, HER2-, CLDN18.2+ Gastric/GEJ Cancer
July 6th 2023The FDA plans to conduct a speedy review of an approval application for zolbetuximab in first-line locally advanced, unresectable, or metastatic HER2-negative, claudin18.2-positive gastric or gastroesophageal junction adenocarcinoma.
Read More
Neoadjuvant Pembrolizumab Plus Chemotherapy Shows Significant Efficacy in GEJ Cancer
June 20th 2023According to phase 3 study results, the combination of pembrolizumab and chemotherapy can induce high rates of response in patients with gastroesophageal junction adenocarcinoma while maintaining safety.
Read More